Investigators reviewed data from 202,237 patients from the Surveillance, Epidemiology, and End Results (SEER) registry who had been diagnosed CRC with 2010 and 2015.
Investigators developed a clinical score to address how to categorize patients with well-differentiated neuroendocrine tumors (NETs) who are being considered for peptide receptor radionuclide therapy (PRRT) and how to sequence therapy.
COBRA investigators will evaluate circulating tumor DNA (ctDNA) as a biomarker for adjuvant chemotherapy benefit in 1408 patients with resected, stable stage IIA colon cancer.
A team of investigators conducted a systematic literature search to assess the cumulative incidence of disease recurrence in patients who underwent local endoscopic resection of early invasive colorectal cancer.
Despite numerous studies showing a potential association between celiac disease and small bowel cancer, there is a lack of data evaluating the risk of specific subtypes of small bowel cancer.
Sean McGowan, senior director of Biosimilars at AmerisourceBergen, and Brian Ansay, senior vice president of Sales and Corporate Services at ION Solutions, review 2020 biosimilar trends in oncology and forecast what is ahead in 2021.
Investigators describe the steps taken to improve clinician referrals to the facility’s outpatient rehabilitation program for patients with GI cancers.
Results presented at the European Society for Medical Oncology Virtual Congress 2020showed significant improvements in the primary endpoints for the pembrolizumab group.
The “watch and wait” approach is characterized by close surveillance without surgery in patients with rectal cancer who achieve a clinical CR following neoadjuvant CRT.
Short-course radiotherapy followed by chemotherapy and total mesorectal excision improved outcomes for patients with high-risk locally advanced rectal cancer.
Researchers have identified actionable alterations in nearly 38% of patients with cancer, and almost 18% of patients were assigned to treatments based on their molecular profiling results.
The survival-inferred fragility index of phase 3 trials for immune checkpoint inhibitors suggests that, despite statistical significance, survival data do not show a robust clinical benefit.
Expertscape, a web platform that used the PubMed database and its patented algorithm to identify and objectively rank physicians and researchers that excel in the treatment and diagnosis of specific disease states, has released their rankings for U.S. physicians who specialize in the research and treatment of colorectal cancer. Using Expertscape’s rigorous process, Douglas Rex, M.D.,…
In response to the rising incidence of CRC in patients younger than 50 years, the USPSTF proposes CRC screening at 45 years as the new clinical standard.
